Clinical Trials

1 enrolled

Plasma cell

Multiple Myeloma

NCT03776487 2026-04-15

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

32 enrolled

Clinical Stage 0 Gastric Cancer AJCC v8

NCT04953104 2026-04-15

ARID1A and/or KDM6A Mutation and CXCL13 Expression

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT04957615 2026-04-15

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

16 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05347212 2026-04-15

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

30 enrolled

Tumor-Agnostic

Carcinoma

NCT06049576 2026-04-15

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

31 enrolled

Carcinoma, Renal Cell

NCT02656706 2026-04-13

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

22 enrolled 10 charts

Melanoma

NCT03650894 2026-04-13

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

30 enrolled

Breast

Breast Neoplasms

NCT04061980 2026-04-13

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

24 enrolled

Head & Neck

Thyroid Neoplasms

NCT05407441 2026-04-13

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

49 enrolled

Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT07523763 2026-04-13

NIVO1002024

30 enrolled

Colorectal Neoplasms

NCT05696548 2026-04-09

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

51 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT05289193 2026-04-07

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

28 enrolled

Melanoma

NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

15 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04709276 2026-04-06

CHAMP

41 enrolled

Prostatic Neoplasms

NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

46 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT03377023 2026-04-02

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

66 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

72 enrolled 16 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03543189 2026-04-01

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

44 enrolled

Prostatic Diseases, Prostatic Neoplasms

NCT05480384 2026-04-01

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

1 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT04963283 2026-03-31

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

48 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03546686 2026-03-27

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

51 enrolled

Breast

Breast Neoplasms

NCT04503694 2026-03-27

REGINA

72 enrolled

Rectal Neoplasms

NCT04930783 2026-03-25

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

10 enrolled

Melanoma

NCT03044613 2026-03-23

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

32 enrolled

Phase 3 Active not recruiting

Esophageal Neoplasms, Stomach Neoplasms

NCT03391869 2026-03-23

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

339 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Phase 3 Active not recruiting

Skin Neoplasms

NCT04637594 2026-03-20

IMAGINE

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT03585465 2026-03-18

Metro-PD1

63 enrolled

Other solid neoplasm

Childhood Solid Tumor

NCT03799445 2026-03-17

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

37 enrolled 12 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT03607890 2026-03-16

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

38 enrolled

Turcot syndrome, Microsatellite Instability

NCT04457284 2026-03-13

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

18 enrolled

Colorectal Adenocarcinoma

NCT03071406 2026-03-11

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

50 enrolled 12 charts

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT04420975 2026-03-10

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

14 enrolled

Sarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

71 enrolled 9 charts

Melanoma

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

DermatologicGenitourinaryThoracic

35 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

99 enrolled

Leukemia, Myelodysplastic Syndromes

NCT03307616 2026-03-05

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

32 enrolled

Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

NCT04013542 2026-03-05

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

21 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05122546 2026-03-05

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

31 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT03223155 2026-03-04

COSINR

78 enrolled

Small Cell Lung Carcinoma

NCT04757363 2026-03-04

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

39 enrolled

Esophageal Neoplasms

NCT06284564 2026-03-04

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

10 enrolled

Carcinoma, Renal Cell

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

Melanoma

NCT04109729 2026-03-02

Rad2Nivo

39 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04969887 2026-02-27

MOST-CIRCUIT

240 enrolled

EndocrineNET

Genital Neoplasms, Female, Neuroendocrine Tumors

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03033914 2026-02-17

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

82 enrolled

Lymphoid

Hodgkin Disease

NCT03520491 2026-02-17

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

52 enrolled